Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03813056 · ClinicalTrials.gov registry record · Phase 2

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

A Phase 2 study of Fuchs Endothelial Dystrophy, sponsored by Michael D. Straiko, MD.

Recruiting
Registry status
Phase 2
Development phase
72
Enrollment target
1
Study location

NCT03813056 is a Phase 2 study of Fuchs Endothelial Dystrophy that is actively recruiting participants, run by Michael D. Straiko, MD. The registered enrollment target is 72 participants, below the 487-participant average among 7 other Fuchs Endothelial Dystrophy trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03813056, a Phase 2 study of Fuchs Endothelial Dystrophy, is actively recruiting participants, sponsored by Michael D. Straiko, MD.

RECRUITING
Registry status
Phase 2
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

Recently, published literature has reported that performing a descemetorhexis in combination with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas in patients with Fuchs Endothelial Corneal Dystrophy. Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor, has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil acts as an IOP-lowering drug by affecting aqueous outflow through the trabecular meshwork and Schlemm's canal. The goal of this study is to test the potential benefits of Ripasudil therapy administered after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. We believe that performing a standard DMEK surgery in combination with Ripasudil treatment in patients with Fuchs Endothelial Corneal Dystrophy could accelerate endothelial cell healing and clear edematous corneas faster, with less post-operative complications.

Conditions Studied

Fuchs Endothelial Dystrophy

Interventions

  • DRUG Glanatec
  • DRUG Optive, Ophthalmic Solution
  • PROCEDURE Descemet Membrane Endothelial Keratoplasty

Study Locations (1)

Oregon

  • Devers Eye Institute - Portland

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2019-03-25
Est. Completion 2025-02-01
Phase Phase 2

Sponsor

Michael D. Straiko, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03813056

The ClinicalTrials.gov registry entry for NCT03813056 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 7 other Fuchs Endothelial Dystrophy trials with a reported enrollment target (85% lower). The listed sponsor is Michael D. Straiko, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fuchs Endothelial Dystrophy appearing as the primary indexed condition, and to 3 interventions - of which Glanatec is the first listed.

NCT03813056 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT03813056 about?

NCT03813056 is a clinical study titled "Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy". Recently, published literature has reported that performing a descemetorhexis in combination with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas in patients with Fuchs Endothelial Corneal Dystrophy. Ripasudil hydrochloride hydrate( Glanatec ophthalmic solut...

What is the current status of trial NCT03813056?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2019-03-25. Estimated completion is 2025-02-01.

What conditions does trial NCT03813056 study?

This clinical trial studies the following conditions: Fuchs Endothelial Dystrophy.

What interventions are being tested in trial NCT03813056?

The interventions under investigation include: Glanatec (DRUG), Optive, Ophthalmic Solution (DRUG), Descemet Membrane Endothelial Keratoplasty (PROCEDURE).

Who is sponsoring clinical trial NCT03813056?

This trial is sponsored by Michael D. Straiko, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03813056 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fuchs Endothelial Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Fuchs Endothelial Dystrophy

All registered trials for this condition

Oregon

All trials with a study site in Oregon

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.